Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Capitalizing on improved biotech sentiment driven by FDA leadership changes, strong M&A including AbbVie's $10.9 billion acquisition of portfolio company Apogee, and positive late-stage oncology data at ASCO.
Full Quick Take
Capitalizing on improved biotech sentiment driven by FDA leadership changes, strong M&A including AbbVie's $10.9 billion acquisition of portfolio company Apogee, and positive late-stage oncology data at ASCO.
RTW Bio outperformed biotech indices despite -6.4% Q1 return as sector valuations hit new lows. Portfolio concentrated in high unmet need rare diseases and oncology with strong FDA support.
Full Quick Take
RTW Bio outperformed biotech indices despite -6.4% Q1 return as sector valuations hit new lows. Portfolio concentrated in high unmet need rare diseases and oncology with strong FDA support.
Outperforming biotech indices. The fund focuses on transformative life sciences assets with 54 core positions spanning genetic medicines, obesity treatments, and rare diseases.
Full Quick Take
Outperforming biotech indices. The fund focuses on transformative life sciences assets with 54 core positions spanning genetic medicines, obesity treatments, and rare diseases.